Prostate Specific Antigen (PSA) antibody

Revolution of PSA/KLK3 diagnosis starts here.

Fig.01 Strong apical predominance of PSA staining in a prostate cancer (0.6 mm tissue microarray spot, immunohistochemistry with clone HAM18)
Fig.02 Intense apical and cytoplasmic PSA staining in a prostate cancer (0.6 mm tissue microarray spot, immunohistochemistry with clone HAM18)
Fig.03 Loss of the apical staining pattern in a prostate cancer (0.6 mm tissue microarray spot, immunohistochemistry with clone HAM18)
More detailed information coming soon.

Clone HAM18 has been developed for detection of prostate specific antigen (PSA) in routine formalin-fixed paraffin-embedded prostate tissue specimen and stands for being the best validated anti-PSA clone. Clone HAM18 has been validated for the important differentiation of apical and cytoplasmic staining patterns in thousands of prostate cancer cases. The data will be presented on PSA-antibody.com quite soon.

Prostate Cancer is the most common cancer in men and PSA is the most important target for management of patients diagnosed with prostate cancer. PSA is a protease exclusively produced in prostate epithelial cells and secreted into the seminal fluid. Moreover, PSA reaches the blood stream and PSA levels have been shown to be proportional to quantity of prostate epithelial cells. Therefore serum analysis has developed the most commonly used method to detect PSA for prostate cancer prevention and to monitor response to therapy. Moreover, PSA immunohistochemistry is an important and common method for routine pathological diagnosis since it allows analysis of cellular expression profiles in prostate cancer.

Menu